Skip to main navigation
Skip to search
Skip to main content
Columbia University Home
Help & FAQ
English
Français
Español
Home
Profiles
Research units
Research output
Equipment
Datasets
Projects & Clinical Trials
Activities
Prizes
Courses
Student theses
Search by expertise, name or affiliation
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
LEGATO-HD Study Group
Vagelos College of Physicians and Surgeons
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Huntington's Disease
100%
Placebo
100%
Laquinimod
100%
Unified Huntington Disease Rating Scale
31%
Least Square Analysis
25%
Adverse Event
18%
Motor Performance
12%
Headache
6%
Functional Status
6%
Arthralgia
6%
Clinical Assessment
6%
Multiple Sclerosis
6%
Clinical Examination
6%
Diarrhea
6%
Laboratory Test
6%
Adenosine
6%
Irritability
6%
Rhinopharyngitis
6%
Pathology of Huntington's Disease
6%
Cardiovascular System
6%
Guanine
6%
Cytosine
6%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Huntington Chorea
100%
Laquinimod
100%
Adverse Event
18%
Diarrhea
6%
Rhinopharyngitis
6%
Functional Status
6%
Headache
6%
Adenosine
6%
Multiple Sclerosis
6%
Guanine
6%
Cytosine
6%
Arthralgia
6%